[Featured Stock] PharmGen Science Soars Over 9%... "Joint mRNA Vaccine Development Agreement with Access Bio and Ivy Pharma"
[Asia Economy Reporter Park Ji-hwan] PharmGen Science is experiencing a surge for the second consecutive day.
According to the Korea Exchange on the 24th, as of 10:31 AM, PharmGen Science is trading at 15,000 KRW, up 9.89% (1,350 KRW). Following the price limit increase the previous day, it is showing a sharp rise for two consecutive trading days.
The strong stock performance this week is interpreted as reflecting PharmGen Science's decision to jointly develop a biosimilar (biopharmaceutical generic) of an mRNA (messenger ribonucleic acid)-based COVID-19 vaccine.
On the 21st (local time in the United States), PharmGen Science announced that it attended the 'Korea-US Global Vaccine Partnership' hosted by the government in New York, USA, and signed an MOU for joint development and commercialization of a COVID-19 vaccine with its US subsidiary Access Bio and the US venture IVY Pharma.
Hot Picks Today
[Breaking] Samsung Electronics Management: "The Principle That Rewards Are Given Where There Are Results Has Been Upheld"
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This MOU centers on PharmGen Science and Access Bio introducing the world's first mRNA COVID vaccine biosimilar candidate secured by IVY Pharma to jointly develop an mRNA COVID vaccine biosimilar.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.